Lilly, BI resubmit diabetes medication

Share this article:

Lilly and Boehringer Ingelheim are resubmitting their experimental SGLT2 diabetes medication empagliflozen to the FDA.

“We are very pleased to move forward . . . following a FDA inspection of the Boehringer Ingelheim facility,” BI president and CEO Paul Fonteyne said in a statement Tuesday, referring to the CRL that halted the FDA's review.

The European Commission greenlighted the diabetes medication, known as Jardiance, in May.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions